Articles tagged "Induction therapy"

2016 American Transplant Congress
Impact of Induction Therapy on Cardiovascular Events in Kidney Transplant Recipients.
S. Sandal,^1,2 S. Bae,² A. Massie,² M. Cantarovich,¹ D. Segev.²
¹MUHC, Montreal, Canada; ²JHU, Baltimore.
Cardiovascular events (CVE) are one of leading causes of mortality in kidney transplant (KT) recipients and ATG use is reported as a risk factor. We…
2016 American Transplant Congress
Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation.
H. Madariaga,¹ R. Ugarte,¹ C. Drachenberg,² N. Costa,¹ B. Thomas,¹ J. Bromberg,³ M. Weir,¹ A. Haririan.¹
¹Department of Medicine, University of Maryland Medical Center, Baltimore, MD; ²Department of Pathology, University of Maryland Medical Center, Baltimore, MD; ³Department of Surgery, University of Maryland Medical Center, Baltimore, MD.
The risk of subclinical histological changes in renal allografts with ALZ induction is not well defined. Hence, we performed a retrospective analysis of 527 surveillance…
2016 American Transplant Congress
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.
L. Mugge, A. Zimmerman, N. Varshney, A. Gohara, M. Rees, J. Ortiz.
Transplantation, The University of Toledo, Toledo, OH.
Background: The highly successful induction drug Alemtuzumab (Campath) is commonly used prior to renal transplant. Yet, it does not completely ablate plasma cell which, in…
2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
F. Al Ammary, S. Bae, A. Massie, N. Desai, N. Dagher, E. Kraus, A. Wiseman, D. Segev.
JHU, Baltimore; CU, Denver.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…
2016 American Transplant Congress
Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.
K. Ayasoufi, V. Gorbacheva, F. Ran, A. Valujskikh.
Cleveland Clinic, Cleveland.
Antibody mediated lymphocyte depletion is commonly used in clinical transplantation. However, memory T cells undermine the efficacy of lymphoablative induction therapies in sensitized transplant recipients.…
2016 American Transplant Congress
Safety, Efficacy, and Cost Saving Potential of Various Weight-Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients.
R. Miller,¹ H. Meadows,¹ S. Strout,¹ T. Veasey,¹ A. Mardis,¹ J. Fleming,¹ C. Mardis,¹ N. Pilch,¹ K. Chavin,² D. Taber.²
¹Department of Pharmacy, Medical University of South Carolina, Charleston, SC; ²Department of Surgery, Medical University of South Carolina, Charleston, SC.
Introduction: There are limited data assessing the appropriate weight to use when dosing Thymoglobulin for induction therapy. The aim of this study is to assess…
2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
M. Willicombe, D. Goodall, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…
2016 American Transplant Congress
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.
B. Chopra, K. Sureshkumar.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Induction therapy improves outcomes in kidney transplant recipients (KTRs) by reducing early acute rejection. In the current era of potent maintenance immunosuppression, the role of…
2016 American Transplant Congress
Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations.
M. McAdams-DeMarco, Q. Huang, X. Luo, B. Orandi, S. Dorry.
Johns Hopkins, Baltimore.
Background: Clinical trials of induction agents typically exclude older recipients, so our practice in older recipients is extrapolated from this. Older adults are different, so…
2016 American Transplant Congress
Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin^®) vs Basiliximab After Kidney Transplantation: A Health Economic Analysis from a German Perspective.
L. Cremaschi,¹ R. Thissen,² T. Benzing,² M. Wiesener,³ N. Zink,³ T. Paivanas,⁴ J. Reitan,⁴ M. Gallagher,⁵ F. Thaiss.¹
¹Univ. Hospital Eppendorf UKE, Hamburg, Germany; ²Univ. Hospital Cologne, Colgone, Germany; ³Univ. Hospital Erlangen-Nürnberg, Erlangen, Germany; ⁴RJM Group, LLC, Washington, DC; ⁵Sanofi-Aventis US, Cambridge, MS.
Study objective. A health economic analysis was undertaken to quantify the economic consequences of acute rejection and serious adverse events in patients receiving induction with…